<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934.
For the quarterly period ended March 31, 2000
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.
For the transition period from ___________to _________.
Commission File Number
0 19777 10 1
ALLOS THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
DELAWARE 54-1655029
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
7000 NORTH BROADWAY, SUITE 400
DENVER, COLORADO 80221
(303) 426-6262
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
As of March 31, 2000, there were 22,837,151 shares of the Registrant's
Common Stock outstanding, par value $0.001 per share.
This quarterly report on Form 10-Q, including exhibits, consists of 14 pages.
The exhibit index is located on page 14.
<PAGE> 2
ALLOS THERAPEUTICS, INC.
FORM 10-Q
INDEX
<TABLE>
<CAPTION>
PAGE
NUMBER
------
<S> <C>
PART I. Financial Information
ITEM 1. Financial Statements ............................................ 3
Balance Sheet --
as of March 31, 2000 (unaudited) and December 31, 1999 ...... 3
Statement of Operations (unaudited) --
for the three months ended March 31, 2000 and 1999 and the
period from inception (September 1, 1992) through
March 31, 2000 .............................................. 4
Statement of Cash Flows (unaudited) -
for the three months ended March 31, 2000 and 1999 and the
period from inception (September 1, 1992) through
March 31, 2000 .............................................. 5
Notes to Financial Statements (unaudited) ....................... 6
ITEM 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations ....................................... 8
PART II. Other Information .................................................. 12
SIGNATURES ................................................................... 13
</TABLE>
Page 2 of 14
<PAGE> 3
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
ALLOS THERAPEUTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEET
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
ASSETS 2000 1999
------------- -------------
(UNAUDITED)
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 66,118,256 $ 2,597,884
Short-term investments 24,573,487 6,877,303
Prepaid expenses - research 842,220 223,117
Prepaid expenses - other 38,992 45,311
Other assets 8,286 185,898
------------- -------------
Total current assets 91,581,241 9,929,513
------------- -------------
Property and equipment (net of accumulated depreciation of $354,313
and $322,227, respectively) 216,484 230,360
Other assets 23,236 45,641
------------- -------------
Total assets $ 91,820,961 $ 10,205,514
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - related parties $ 4,842 $ 8,087
Accrued expenses - research 703,676 768,592
Accounts payable - trade 959,939 65,123
Accrued compensation and employee benefits 138,065 224,379
Current portion of capital lease obligations 71,795 79,042
------------- -------------
Total current liabilities 1,878,317 1,145,223
Long-term portion of capital lease obligations 53,421 69,320
------------- -------------
Total liabilities 1,931,738 1,214,543
Stockholders' equity:
Convertible preferred stock, Series A: $0.001 par value, 0 and
5,000,000 shares authorized, issued and outstanding at March 31,
2000 and December 31, 1999, respectively (liquidation value:
$6,718,107 at December 31, 1999) -- 5,000
Convertible preferred stock, Series B: $0.001 par value, 0 and
5,050,000 shares authorized at March 31, 2000 and December 31,
1999, respectively; 0 and 5,032,500 shares issued and
outstanding at March 31, 2000 and December 31, 1999,
respectively (liquidation value: $10,191,261 at December 31,
1999) -- 5,033
Convertible preferred stock, Series C: $0.001 par value, 0 and
16,610,000 shares authorized at March 31, 2000 and December 31,
1999, respectively; 0 and 15,255,786 shares issued and
outstanding at March 31, 2000 and December 31, 1999,
respectively (liquidation value: $30,161,846 at December 31,
1999) -- 15,256
Preferred stock, $0.001 par value; 10,000,000 shares authorized at
March 31, 2000, no shares issued or outstanding -- --
Common stock, $0.001 par value; 75,000,000 and 31,000,000 shares
authorized at March 31, 2000 and December 31, 1999,
respectively; 22,837,151 and 2,022,138 shares issued and
outstanding at March 31, 2000 and December 31, 1999,
respectively 22,837 2,022
Additional paid-in capital preferred stock -- 49,873,495
Additional paid-in capital common stock 156,549,356 7,020,291
Notes receivable - related parties (49,687) (139,687)
Accumulated deficit (54,824,893) (43,348,145)
Deferred compensation related to grant of options (11,808,390) (4,442,294)
------------- -------------
Total stockholders' equity 89,889,223 8,990,971
------------- -------------
Total liabilities and stockholders' equity $ 91,820,961 $ 10,205,514
============= =============
</TABLE>
The accompanying notes are an integral part of these financial statements.
Page 3 of 14
<PAGE> 4
ALLOS THERAPEUTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
CUMULATIVE
PERIOD FROM
SEPTEMBER 1,
1992 (DATE OF
INCEPTION)
THREE MONTHS ENDED THROUGH
MARCH 31, MARCH 31,
2000 1999 2000
------------ ------------ ------------
<S> <C> <C> <C>
Operating expenses:
Research and development $ 3,846,617 $ 1,977,307 $ 26,792,504
Clinical manufacturing 344,978 408,174 5,509,811
General and administrative 7,400,506 427,767 14,571,239
------------ ------------ ------------
Total operating expenses 11,592,101 2,813,248 46,873,554
Loss from operations (11,592,101) (2,813,248) (46,873,554)
Interest and other income, net 115,353 95,096 1,661,636
------------ ------------ ------------
Net loss (11,476,748) (2,718,152) (45,211,918)
Dividend related to beneficial conversion
feature of preferred stock -- -- (9,612,975)
------------ ------------ ------------
Net loss attributable to common stockholders $(11,476,748) $ (2,718,152) $(54,824,893)
============ ============ ============
Net loss per common share:
Basic and diluted $ (3.51) $ (1.37)
============ ============
Weighted average common shares - basic
and diluted 3,270,720 1,981,753
============ ============
</TABLE>
The accompanying notes are an integral part of these financial statements.
Page 4 of 14
<PAGE> 5
ALLOS THERAPEUTICS, INC.
(A DEVELOPMENT STATE COMPANY)
STATEMENT OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
CUMULATIVE PERIOD
FROM SEPTEMBER 1,
1992 (DATE OF
THREE MONTHS ENDED INCEPTION) THROUGH
MARCH 31, MARCH 31,
2000 1999 2000
------------- ------------- ------------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $ (11,476,748) $ (2,718,152) $ (45,211,918)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization 32,086 36,124 384,108
Stock-based compensation expense 9,625,110 -- 11,993,871
Other -- -- 52,406
Changes in operating assets and liabilities:
Decrease (increase) in prepaids and other assets (412,768) (180,574) (912,735)
(Increase) decrease in interest receivable on
short-term investments (180,912) 12,778 (275,404)
Increase (decrease) in accounts payable - related
parties (3,245) (112,196) 4,842
Increase (decrease) in accrued expenses - research (64,916) 166,061 703,676
Increase (decrease) in accounts payable - trade 894,815 (56,883) 959,938
Increase (decrease) in accrued compensation and
employee benefits (86,314) 36,191 138,065
------------- ------------- -------------
Net cash used in operating activities (1,672,892) (2,816,651) (32,163,151)
------------- ------------- -------------
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of property and equipment (18,209) (6,324) (311,401)
Purchase of short-term investments (20,447,522) (1,966,000) (68,384,700)
Proceeds from sale of short-term investments 2,932,250 4,904,824 44,086,617
------------- ------------- -------------
Net cash provided by (used in) investing
activities (17,533,481) 2,932,500 (24,609,484)
------------- ------------- -------------
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments under capital leases (23,145) (29,207) (296,871)
Proceeds from sale leaseback -- -- 120,492
Proceeds from stockholder loan -- -- 12,000
Repayment of stockholder loan -- -- (12,000)
Proceeds from issuance of convertible preferred
stock, net of issuance costs (2,503) (2,804) 40,283,306
Proceeds from issuance of common stock, net of
issuance costs 82,752,393 -- 82,783,964
------------- ------------- -------------
Net cash provided by (used in) financing
activities 82,726,745 (32,011) 122,890,891
------------- ------------- -------------
Net increase (decrease) in cash 63,520,372 83,838 66,118,256
Cash and cash equivalents, beginning of period 2,597,884 1,656,546 --
------------- ------------- -------------
Cash and cash equivalents, end of period $ 66,118,256 $ 1,740,384 $ 66,118,256
============= ============= =============
SUPPLEMENTAL SCHEDULE OF NONCASH OPERATING
AND FINANCING ACTIVITIES
Issuance of stock in exchange for license agreement -- -- 40,000
Capital lease obligations incurred for purchase of
property and equipment -- -- 422,088
Issuance of stock in exchange for notes receivable -- -- 139,687
</TABLE>
The accompanying notes are an integral part of these financial statements.
Page 5 of 14
<PAGE> 6
ALLOS THERAPEUTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
1. BASIS OF PRESENTATION
The accompanying unaudited financial statements of Allos Therapeutics,
Inc., referred to herein as we, us or our, have been prepared pursuant to the
rules and regulations of the Securities and Exchange Commission ("SEC"). Certain
information and footnote disclosures normally included in financial statements
prepared in accordance with generally accepted accounting principles have been
condensed or omitted pursuant to such rules and regulations. However, the
Company believes that the disclosures are adequate to make the information
presented not misleading. The unaudited financial statements included herein
have been prepared on the same basis as the annual financial statements and
reflect all adjustments, which include only normal recurring adjustments
necessary for a fair presentation in accordance with generally accepted
accounting principles. The results for the three-month period ended March 31,
2000 are not necessarily indicative of the results expected for the full fiscal
year. These financial statements should be read in conjunction with the December
31, 1999 audited financial statements and the notes thereto included in the
Company's Form S-1 filed with the SEC on March 27, 2000.
The Company has not generated any revenue to date and its activities have
consisted primarily of developing products, raising capital and recruiting
personnel. Accordingly, the Company is considered to be in the development stage
at March 31, 2000 as defined in Statement of Financial Accounting Standards No.
7, "Accounting and Reporting by Development Stage Enterprises".
2. EARNINGS PER COMMON SHARE
Basic earnings per common share is computed using the weighted average
number of common shares outstanding during the period. Diluted earnings per
common share is computed using the weighted average number of common and
potential common shares outstanding during the period. Potential common shares
consist of stock options and warrants and have been excluded from the
computation of diluted earnings per common share because their effect was
anti-dilutive.
3. INITIAL PUBLIC OFFERING
On March 27, 2000, the SEC declared effective the Company's Registration
Statement on Form S-1. Pursuant to this Registration Statement, the Company
completed an Initial Public Offering ("IPO") of 5,000,000 shares of its common
stock at an IPO price of $18.00 per share (the "Offering"). Proceeds to the
Company from the Offering, after calculation of the underwriters' discount and
commission, totaled approximately $82.7 million, net of offering costs of
approximately $1 million. Concurrent with the closing of the IPO, all
outstanding shares of the Company's convertible preferred stock were
automatically converted into 15,678,737 shares of common stock.
Page 6 of 14
<PAGE> 7
4. RELATED PARTY TRANSACTIONS
In March 1996, the Company obtained recourse notes receivable (the "1996
Notes") from two officers in the amount of $90,000 upon the officers' exercise
of 558,000 stock options. The notes accrued interest at 8% annually with
interest and principal originally due March 1998. In December 1997, the maturity
dates for the 1996 Notes were extended by two years and extended by an
additional year in January 2000. In March 2000, the 1996 Notes were forgiven. In
connection therewith, the Company recorded $7,617,000 in stock compensation
expense for the period ended March 31, 1999 based on the difference between the
fair market value of the underlying common stock and option exercise prices.
This expense was allocated as $2,200,000 related to research and development and
$5,417,000 related to general and administrative.
In December 1997, the Company obtained additional notes receivable (the "1997
Notes") from these officers in the amount of $49,687 upon the officers' exercise
of stock options to acquire 123,225 shares. These notes accrued interest at 6%
annually with interest and principal originally due December 1999. The 1997
Notes are classified as an offset to stockholders' equity. The maturity dates
for the 1997 Notes were extended by one year in January 2000, however, we do not
intend to extend the 1997 notes a second time.
Page 7 of 14
<PAGE> 8
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following Management's Discussion and Analysis of Financial Condition
and Results of Operations as well as information contained elsewhere in this
report, contains statements that constitute "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. You can identify
these statements by forward-looking words such as "may," "will," "expect,"
"intend," "anticipate," "believe," "estimate," "plan," "could," "should" and
"continue" or similar words. Actual results could differ materially from those
anticipated in these forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, those mentioned
in the discussion below and those described in the "Risk Factors" discussion of
our Registration Statement on Form S-1 filed with the Securities and Exchange
Commission. As a result, you should not place undue reliance on these
forward-looking statements. We do not intend to update or revise these
forward-looking statements to reflect future events or developments.
OVERVIEW
We are a pharmaceutical company focused on developing and commercializing
innovative small molecule drugs initially for improving cancer treatments. Our
lead product candidate is RSR13. RSR13 is a synthetic small molecule that
increases the release of oxygen from hemoglobin, the oxygen carrying protein
contained within red blood cells. We believe RSR13 can be used to improve
existing treatments for cancer and treat many diseases attributed to or
aggravated by tissue oxygen deprivation.
To date, we have devoted substantially all of our resources to research and
clinical development. We have not derived any commercial revenues from product
sales, and we do not expect to receive product revenues for at least the next
several years. We have incurred significant operating losses since our inception
in 1992 and, as of March 31, 2000, had an accumulated deficit of $54,824,893.
There can be no assurance if or when we will become profitable. We expect to
continue to incur significant operating losses over the next several years as we
continue to incur increasing research and development costs, in addition to
costs related to clinical trials and manufacturing activities. We expect that
losses will fluctuate from quarter to quarter and that such fluctuations may be
substantial. Our achieving profitability depends upon our ability, alone or with
others, to successfully complete the development of our product candidates, and
obtain required regulatory clearances and successfully manufacture and market
our future products.
RESULTS OF OPERATIONS
Expenses
Research and Development
Research and development expenses increased to $3,847,000 for the three
months ended March 31, 2000 from $1,977,000 for the three months ended March 31,
1999 due primarily to non-cash charges comprising amortization of deferred
compensation expense of $571,000 and stock compensation expense of $2,234,000
resulting from the forgiveness of the 1996 Notes (see Note 4 to the Financial
Statements).
Page 8 of 14
<PAGE> 9
Excluding the impact of the non-cash charges, research and development
expenses decreased $937,000, or 47%, to $1,040,000 in the three months ended
March 31, 2000 as compared to $1,977,000 in the three months ended March 31,
1999. This decrease was primarily due to lower clinical trial costs resulting
from the completion of several Phase II clinical trials that were ongoing during
the same period last year.
Clinical Manufacturing
Clinical manufacturing expenses include the cost of manufacturing RSR13 for
use in clinical trials and costs associated with the scale-up of manufacturing
to support commercial requirements. Clinical manufacturing expenses for the
three months ended March 31, 2000 and 1999 were $345,000 and $408,000,
respectively. The $63,000, or 15% decrease is attributable to lower RSR13
requirements resulting from reduced clinical trials.
General and Administrative
General and administrative expenses were $7,401,000 for the three months
ended March 31, 2000 compared to $428,000 for the three months ended March 31,
1999. The $6,973,000 increase was due primarily to non-cash charges comprising
amortization of deferred compensation expense of $1,306,000 and stock
compensation expense of $5,502,000 resulting from the forgiveness of the 1996
Notes (see Note 4 to the Financial Statements).
Excluding the impact of the non-cash charges, general and administrative
expenses increased $165,000, or 39%, to $593,000 in the three months ended March
31, 2000 as compared to $428,000 in the three months ended March 31, 1999. This
increase is a result of additional consulting expenses incurred for investor and
public relations as well as increased personnel and travel expenses.
Non-cash Charges
In March 1996, we obtained recourse notes receivable (the "1996 Notes")
from two officers in the amount of $90,000 upon the officers' exercise of
558,000 stock options. The 1996 Notes accrued interest at 8% annually with
interest and principal originally due March 1998. In December 1997, the maturity
dates for the 1996 Notes were extended by two years and extended by an
additional year in January 2000. In March 2000, the 1996 Notes were forgiven. In
connection therewith, we recorded $7,617,000 in stock compensation expense for
the period ended March 31, 1999 based on the difference between the fair market
value of the underlying common stock and option exercise prices.
In the first quarter 2000, we recorded amortization of deferred stock
compensation of $1,918,000 in connection with the grant of certain options to
employees prior to the IPO with exercise prices below the fair value for
financial reporting purposes of our common stock on their respective grant
dates.
Interest and Other Income, Net
Interest income, net of interest expense, increased by 21% to $115,000 for
the quarter ended March 31, 2000 from $95,000 for the quarter ended March 31,
1999. This increase was primarily a result of increased average investment
balances and higher yields on U.S. government securities, high-grade commercial
paper and money market funds held by us.
Page 9 of 14
<PAGE> 10
LIQUIDITY AND CAPITAL RESOURCES
Since inception, we have financed the operations primarily through private
placements of preferred stock, which has resulted in net proceeds of $40,283,000
through March 31, 2000. On March 27, 2000, the SEC declared effective our
Registration Statement on Form S-1. Pursuant to this Registration Statement, we
completed an IPO of 5,000,000 shares of common stock at an IPO price of $18.00
per share. We received proceeds from the Offering, after calculation of the
underwriters' discount and commission, totaling approximately $82.7 million, net
of offering costs of approximately $1 million.
As of March 31, 2000, we had approximately $90,692,000 in cash, cash
equivalents and short-term investments. Net cash used in operating activities of
$1,673,000 during the three months ended March 31, 2000 resulted primarily from
the net loss for the period and an increase in deposits for future manufacturing
runs of bulk drug substance. Net cash used in operating activities of $2,817,000
during the three months ended March 31, 1999 resulted primarily from the net
loss for the period.
Net cash used in investing activities of $17,553,000 for the three months
ended March 31, 2000, consisted primarily of purchases of investments, net of
proceeds. Net cash provided by investing activities of $2,933,000 for the three
months ended March 31, 1999, consisted primarily of proceeds from the sale of
investments, net of purchases.
Net cash provided by financing activities of $82,727,000 for the three
months ended March 31, 2000 primarily resulted from the sale of common stock
which was offset by payments under our capital lease obligations.
Based upon the current status of our product development and
commercialization plans, we believe cash, cash equivalents and investments will
be adequate to satisfy our capital needs through at least the calendar year
2001. However, our actual capital requirements will depend on many factors,
including the status of product development; the time and cost involved in
conducting clinical trials and obtaining regulatory approvals; filing,
prosecuting and enforcing patent claims; competing technological and market
developments; and our ability to market and distribute our future products and
establish new collaborative and licensing arrangements.
Our forecast of the period of time through which our financial resources
will be adequate to support our operations is a forward-looking statement that
involves risks and uncertainties, and actual results could vary materially. The
factors described above will impact our future capital requirements and the
adequacy of our available funds. We may be required to raise additional funds
through public or private financings, collaborative relationships or other
arrangements. There can be no assurance that such additional funding, if needed,
will be available on terms attractive to us, or at all. Furthermore, any
additional equity financing may be dilutive to existing stockholders and debt
financing, if available, may involve restrictive covenants. Collaborative
arrangements, if necessary to raise additional funds, may require us to
relinquish rights to certain of our technologies, products or marketing
territories. Our failure to raise capital when needed could have a material
adverse effect on our business, financial condition and results of operations.
MARKET RISK
Our cash, cash equivalents and investments are comprised primarily of
short-term fixed rate instruments. Accordingly, we are not subject to interest
rate risk to any significant degree.
Page 10 of 14
<PAGE> 11
RISK FACTORS
In addition to the other information contained in this report, we caution
stockholders and potential investors that the following important factors, among
others, in some cases have affected, and in the future could affect, our actual
results of operations and could cause our actual results to differ materially
from those expressed in any forward-looking statements made by, on, or on behalf
of us. The following information is not intended to limit in any way the
characterization of other statements or information under other captions as
cautionary statements for such purpose. These factors include:
o Delay, difficulty, or failure to obtain regulatory approval or
clearance to market our product candidates; including delays or
difficulties in development because of insufficient proof of safety or
efficacy.
o Our limited experience in conducting and managing clinical trials;
failure to conduct clinical trials in compliance with applicable
regulations and at an acceptable cost.
o The ability to obtain, maintain and enforce intellectual property
rights; the cost of acquiring in-process technology and other
intellectual property rights, either by license, collaboration or
purchase of another entity; the cost of enforcing or defending our
intellectual property rights.
o Failure of third party collaborators to conduct research and
development activities, including drug discovery and clinical testing;
conflicts of interest or priorities that may arise between us and such
third party collaborators.
o Dependence upon third parties to manufacture RSR13 bulk drug substance
and formulated drug product; failure of third parties to manufacture
RSR13 bulk drug substance or formulated drug product in compliance
with regulatory requirements and at an acceptable cost; failure of
third parties to supply sufficient quantities of RSR13 bulk drug
substance or formulated drug product for preclinical, clinical or
commercial purposes; failure to establish alternative sources of
supply of RSR13 bulk drug substance or formulated drug product.
o The ability to create sales, marketing and distribution capabilities
for our product candidates, or enter into agreements with third
parties to perform these functions;
o The ability to obtain acceptable prices or adequate levels of
reimbursement for our products from third party payors, including
government and health administration authorities and private health
insurers.
o Difficulties or high cost of obtaining adequate financing to fund
future research, development and commercialization of product
candidates.
o Competitive or market factors that may limit the use or broad
acceptance of our product candidates.
o The ability to attract and retain highly qualified management and
scientific personnel.
Page 11 of 14
<PAGE> 12
PART II. OTHER INFORMATION
Item 1. Legal Proceedings None
Item 2. Changes in Securities None
Item 3. Defaults Upon Senior Securities None
Item 4. Submission of Matters to a Vote of
Security Holders None
Item 5. Other Information None
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits 27 (Financial Date Schedule)
(b) Reports on Form 8-K None
Page 12 of 14
<PAGE> 13
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended, (the "Exchange Act") the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: May 12, 2000 ALLOS THERAPEUTICS, INC.
/s/ Stephen J. Hoffman
---------------------------------------
Stephen J. Hoffman, PhD, MD
President and Chief Executive Officer
/s/ Michael E. Hart
---------------------------------------
Michael E. Hart
Chief Financial Officer and Sr. Vice
President, Operations
/s/ Paulette M. Wilson
---------------------------------------
Paulette M. Wilson
Controller
Page 13 of 14
<PAGE> 14
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
- ----------- -----------
<S> <C>
27 FINANCIAL DATA SCHEDULE
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<CASH> 66,118,256
<SECURITIES> 24,573,487
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 91,581,241
<PP&E> 570,797
<DEPRECIATION> 354,313
<TOTAL-ASSETS> 91,820,961
<CURRENT-LIABILITIES> 1,878,317
<BONDS> 53,421
0
0
<COMMON> 156,522,506
<OTHER-SE> (66,633,283)
<TOTAL-LIABILITY-AND-EQUITY> 91,820,961
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 11,476,748
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 8,093
<INCOME-PRETAX> (11,476,748)
<INCOME-TAX> 0
<INCOME-CONTINUING> (11,476,748)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (11,476,748)
<EPS-BASIC> (3.51)
<EPS-DILUTED> (3.51)
</TABLE>
